Pegfilgrastim (Y-shaped pegylation) - Xiamen Amoytop Biotech

Drug Profile

Pegfilgrastim (Y-shaped pegylation) - Xiamen Amoytop Biotech

Alternative Names: Y-shaped branched pegylated filgrastim; YPEG-filgrastim; YPEG-rhG-CSF

Latest Information Update: 18 Dec 2015

Price : $50

At a glance

  • Originator Xiamen Amoytop Biotech
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 18 Dec 2015 Phase-II development is ongoing in China
  • 06 Dec 2013 Phase-II clinical trials in Neutropenia (chemotherapy-induced) in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top